NEWS
MOVERS & SHAKERS
People
Geert Dancet has been appointed secretary general of the Helsinki Chemicals Forum, the international event for chemical safety and chemical management. Previously, executive director of The European Chemicals Agency (ECHA), Dancet will be responsible for developing the Finnish event with a programme of moderated panels, discussions and keynote presentations.
California-based biotechnology company Alkahest, which specialises in developing treatments for neurodegenerative diseases and other age-related conditions, has appointed Karl G. Trass as vp, regulatory affairs, and Jonas Hannestad as senior medical director.
Biopharmacetical company Anokion, a spin-off from Ecole Polytechnique Fédérale de Lausanne (EPFL), which is developing tolerance-inducing therapeutics for autoimmune diseases, has appointed John Hohneker as president and CEO.
German medical device company GILUPI, which focuses on the cancer diagnostics market, has appointed Christian Jurinke as CEO. He has around 20 years’ experience of the biomedical industry in both technical and commercial positions.
Scientific publisher John Wiley & Sons has announced that Cyrille Boyer, professor of chemical engineering at the University of New South Wales Sydney, Australia, is the winner of the sixth Polymer International-IUPAC award for Creativity in Applied Polymer Science or Technology. In addition, Dionissios Mantzavinos, professor of wastewater engineering at the University of Patras, Greece, is the new editor-in-chief of Wiley’s Journal of Chemical Technology and Biotechnology, and Timothy Long, professor of chemistry at Virginia Tech, US, is the new editor-in-chief for Polymer International.
Edinburgh-based synthetic biology company, Synpromics, has appointed Sarah Haecker Meeks, as vp, business development. Meeks has expertise in the design and development of gene medicines.
MSD Research Laboratories, a tradename of Merck, headquartered in the Kenilworth, NJ, US, has appointed Fiona Marshall to lead its new discovery research facility in London, UK, expected to open in 2020. She joins MSD from Sosei, where she was executive vp and CSO. She is renowned for her work in GProtein- Coupled-Receptor (GPCR) biology, an active area of drug research, and has more than 25 years’ experience in industrial drug discovery.
US biotechnology company, BioClin Therapeutics, which specialises in developing protein therapy for the treatment of bladder cancer, has appointed Graeme Currie as COO and Esteban (Steve) Abella as CMO.
Kevin Doyle is the new head of chemistry at the drug discovery services company Domainex, based in Cambridge, UK. He is a medicinal chemist with more than 20 years’ experience in leading drug discovery projects in the pharmaceuticals industry.
Gene therapy company, Voyager Therapeutics, headquartered in Cambridge, Massachusetts, US, has announced that Steven Paul will change roles, from president and CEO to executive science advisor, during 2018. Paul will continue to serve on Voyager’s board of directors, and as a member of the science & technology committee. He will remain in his current role until a new CEO has been appointed.
Hikma Pharmaceuticals, headquartered in London, UK, has appointed Surendera Tyagi as CSO and global head of R&D. Tyagi will focus on the group’s non-injectables business during the first year and will become a member of Hikma’s executive committee.
Global life sciences company, Sanofi has promoted Dominique Carouge to executive vp and head of business transformation. He was formerly deputy CFO and head of finance operations.
Thomas Engber has joined US-based biotechnology company, Disarm Therapeutics, as senior vp and head of neuropharmacology and translational sciences.
Biotechnology company, Orchard Therapeutics, based in the UK and in the US, has appointed Harry Malech to its scientific advisory board (SAB). Malech is a recognised for his work in primary immune deficiencies (PIDs) and gene therapy.
UK-headquartered Redx, a drug discovery and development company focused on cancer and fibrosis, has appointed Andrew Saunders as CMO. He has over 25 years’ experience in the clinical development of oncology drugs.
US-headquartered Rx-360, an international pharmaceutical supply chain consortium set up in 2009 to ensure a commitment to patient safety, has appointed James (Jim) M. Fries as CEO/COO. Fries will lead the organisation of 300 volunteers from over 100 institutions in the US, Europe, China and India.
UK process engineering company, BPE, which specialises in the chemical and life sciences sectors, has appointed Andrew Stevenson as biochemical engineering senior consultant. With over 25 years’ experience, he will be responsible for projects, ranging from front end design and manufacturing strategy to safety and simulation.
Swedish contract research organisation, TFS International, headquartered in Lund, has appointed János Filakovský as CEO. Filakovský has over 20 years’ experience working in the life sciences industry.
London, UK, headquartered IXICO, the digital technologies company serving neuroscience, has announced that Derek Hill, one of the company’s founders, is stepping down from the board as executive director. He will maintain his relationship with IXICO in a scientific advisory capacity.
China biotechnology company, KBP Biosciences has appointed Brian P. McVeigh as CEO. He has over 25 years’ experience in business development, finance, marketing, corporate and R&D organisations at GlaxoSmithKline (GSK).
14
02 | 2018
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
